Scientific observations on PI3K signalling in cancer have resulted in the development of a number of PI3K pathway inhibitors over the past 15 years, including isoform-specific inhibitors, which are now in clinical trials across a spectrum of haematological malignancies (a selection of recent trials is highlighted in Table 2). This evidence concerns the gene PIK3CB and cancer.